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The pharmacokinetics of beta-lactam antibiotics in intensive care patients may be profoundly altered due to the
dynamic, unpredictable pathophysiological changes that occur in critical illness. For many drugs, significant
increases in the volume of distribution and/or variability in drug clearance are common. When “standard”
beta-lactam doses are used, such pharmacokinetic changes can result in subtherapeutic plasma concentrations,
treatment failure, and the development of antibiotic resistance. Emerging data support the use of beta-lactam
therapeutic drug monitoring (TDM) and individualized dosing to ensure the achievement of pharmacodynamic
targets associated with rapid bacterial killing and optimal clinical outcomes. The purpose of this work was to
describe the pharmacokinetic variability of beta-lactams in the critically ill and to discuss the potential utility of TDM
to optimize antibiotic therapy through a structured literature review of all relevant publications between 1946 and
October 2011. Only a few studies have reported the utility of TDM as a tool to improve beta-lactam dosing in
critically ill patients. Moreover, there is little agreement between studies on the pharmacodynamic targets required
to optimize antibiotic therapy. The impact of TDM on important clinical outcomes also remains to be
established. Whereas TDM may be theoretically rational, clinical studies to assess utility in the clinical setting are
urgently required.
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Introduction
Emerging evidence suggests that optimizing antibiotic
dosing may be a key intervention to improve outcomes
in patients with sepsis and septic shock [1-7]. Nonethe-
less, dose optimization in this critically ill population
remains a significant clinical challenge.
Pathophysiological alterations associated with critical
illness can lead to both an increase in the apparent vol-
ume of distribution of an antibiotic as well as in clear-
ance; thus potentially leading to subtherapeutic plasma
concentrations at the site of infection, treatment failure,
and the development of antibiotic resistance [8-11].
Conversely, the development of renal and/or hepatic* Correspondence: j.roberts2@uq.edu.au
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in any medium, provided the original work is pimpairment may be associated with the rapid onset of
toxic drug concentrations.
Despite considerable knowledge of the potential issues
associated with inadequate antibiotic dosing and the
consequences of therapeutic failure, clinicians have little
data to guide practice. Although antibiotics are adminis-
tered frequently in the critically ill [12], to date only a
limited number of pharmacokinetic (PK) studies have
been undertaken. Instead, the focus has largely been on
the avoidance of toxicity from elevated drug concentra-
tions. Accordingly, the available dosing guidelines often
are based on PK data obtained from healthy volunteers
or noncritically ill patients, with little consideration for
the sepsis-induced PK changes that may occur [13].
Moreover, interindividual PK variability in the critically
ill, and the consequent unpredictability of drug concen-
trations, suggests that an empirical fixed dose strategy is
unlikely to be successful [14,15].Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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therapeutic drug monitoring (TDM) to optimize dosing
for drugs with a narrow therapeutic index (e.g., amino-
glycosides, glycopeptides), limited data are available
regarding TDM of antibiotics with wider therapeutic in-
dices, such as the beta-lactam class of antibiotics [13].
TDM for these antibiotics has been traditionally seen as
unnecessary. However, recent data suggest that there is a
relationship between beta-lactam antibiotic target expos-
ure and clinical outcomes in the critically ill. In addition,
the reported PK variability of these antibiotics suggests
that many patients do not achieve their target exposures.
Although published opinion supports the use of TDM
to optimize antibiotic therapy for drugs not traditionally
subject to TDM (i.e., beta-lactams) [15-17], this role has
not been subjected to a structured literature review.Purpose
The purpose of this review is to describe the PK variabil-
ity of beta-lactam antibiotics and to discuss the potential
utility of TDM to optimize therapy for critically ill
patients.Search strategy and results
Medline (1946 to October 2011), Embase (1947 to Octo-
ber 2011), and the Cochrane Central Registry of Con-
trolled Trials databases were searched for key words to
extract data. The search terms were: (1) Pharmacoki-
netic*, pharmacodynamic*, concentration*, clearance,
volume of distribution, target concentration interven-
tion, therapeutic drug monitoring, therapeutic drug
management, dosing, dose, kinetics; (2) beta-lactam*,
antimicrobial*, antibacterial*, antibiotic*, ampicillin,
dicloxacillin, penicillin, flucloxacillin, piperacillin, cepha-
lothin, cefazolin, ceftriaxone, ceftazidime, cefepime, mer-
openem, ertapenem and; (3) intensive care, critically ill,
critical illness, critical care, sepsis, septic shock, h(a)
emofiltration, intermittent hemodialysis, extended dialy-
sis, sustained low-efficiency dialysis, slow-flow dialysis.
Each search was limited to the English language and
human studies. Finally searches (1), (2), and (3) were
combined. Studies from the extensive files of the authors
also were eligible for inclusion. A total of 158 original
research articles describing the PK and pharmacodynam-
ics (PK/PD) of beta-lactam antibiotics in critically
ill patients were reviewed for qualitative synthesis
(Figure 1). A relatively large number of studies related
to the PK/PD of cefepime, ceftazidime, meropenem,
and piperacillin in the critically ill. However, there was
limited published data for many commonly prescribed
antibiotics, which tend to be of narrower spectrum (i.e.,
ampicillin, cephalothin, cefazolin, ceftriaxone, dicloxacillin,
ertapenem, flucloxacillin, penicillin; Figure 2).PK/PD variability of beta-lactam antibiotics in the
critically ill
Significant, unpredictable, beta-lactam PK variability is
well-documented in the critically ill (Table 1). Increase
in the volume of distribution (potentially by several-fold)
is common [18-27] primarily due to expansion of the
extracellular fluid volume (edema). Elimination half-life
also can be prolonged due to the increased volume of
distribution [21,28-30]. Conversely, clearance may be
unchanged [21], decreased [20,22] or even elevated as a
result of augmented renal clearance (ARC) in the hyper-
dynamic phase of sepsis (resulting in sub-therapeutic
concentrations of renally cleared antibiotics) [24-26,31].
Enhanced elimination also can be due to a
hypoalbuminemia-related reduction in protein binding,
particular for highly bound antibiotics, such as flucloxa-
cillin and ceftriaxone [27,28,32].
Whereas some studies have reported achievement of
PD targets in the critically ill with standard beta-lactam
dosing strategies used for noncritically ill patients
[20,40,41], many others have demonstrated that such
empiric antibiotic dosing is insufficient to achieve appro-
priate PD targets [20,26,27,36,42-48]. These divergent
reports reflect the significant interpatient PK variability
that occurs in the critically ill. Treatment failure with in-
appropriate dosing is of particular concern for pathogens
with a high minimum inhibitory concentration (MIC)
[14,49]. Septic patients also may benefit from higher
doses, particularly in the initial 24–48 hours of therapy
[38,42,43,50]. Of note, however, even with an increased
dose, the attainment of PD targets may still be unreli-
able, because beta-lactams have predominantly time-
dependent kill characteristics, i.e., the time that the
unbound (or free) concentration is above the MIC
( fT>MIC) is the major PK/PD index associated with bac-
terial killing [51-53]. Consequently, the goal of beta-
lactam dosing is to optimize the duration of exposure
above the MIC during the dosing interval. Increased
time above MIC may be achieved by more frequent
dosing or by changing the mode of administration from
an intermittent bolus injection to either an extended or
continuous infusion. The PK of beta-lactam continuous
infusions has been most extensively studied for ceftazidime
[35,54-59]. However, the clinical superiority of a continu-
ous infusion (versus intermittent injection) for beta-
lactams is yet to be established [60].
A further consideration for optimizing antibiotic ex-
posure relates to antibiotic penetration into the intersti-
tial fluid (ISF) of tissues, which is the site of most
infections. Data show antibiotic concentrations in ISF
that are two- to tenfold lower than plasma concentra-
tions, suggesting that higher plasma concentrations may
be required to ensure target concentrations in ISF
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population than critically ill septic patients










33 Excluded because they are conference/review papers, editorials, 
commentary, or letters to the editor. 
Reviewed for qualitative synthesis
(Distribution of antibiotics given in Figure2)
Figure 1 Identification, screening, and selection of articles for the systematic review.
Sime et al. Annals of Intensive Care 2012, 2:35 Page 3 of 11
http://www.annalsofintensivecare.com/content/2/1/35antibiotic doses based on presumed ISF distribution.
Problematic to such an approach is that antibiotic con-
centrations appears to vary between different tissues,
suggesting that different plasma target concentrations
may be required for the same bacteria depending on the
tissue that is the source of infection.
PK alterations in acute kidney injury
Acute kidney injury occurs in approximately 5% of crit-
ically ill patients and results in significant PK variability
for many beta-lactams. Clearance may be extensivelyreduced, leading to both drug accumulation and toxicity
[63-65]. In patients receiving continuous renal replace-
ment therapy (CRRT), extracorporeal clearance is signifi-
cant, yet variable. Efficient clearance of cefepime [66-68],
ceftazidime [69,70], meropenem [71-73], and piperacillin
[74,75] has been reported. Ceftriaxone clearance also has
been shown to be higher than expected [76,77]. In con-
trast, CRRT clearance for the highly protein-bound flu-
cloxacillin is minimal [78,79].
It should be noted, however, that it is difficult to com-































Figure 2 Number of articles describing pharmacokinetics and
pharmacodynamics of selected beta-lactam antibiotics in
critically ill patients (relates to Figure 1).
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used, operational parameters, and modes of dialysis
(Table 2). The consequent unreliable beta-lactam dose
prediction for individual patients [80,81] is furtherTable 1 Pharmacokinetic parameters of selected beta-lactam
dysfunction






Cefepime 12 2 g q12h 0.34* 123 3.
19 2 g q8h 0.36 88.2* 3.
13 2 g q12h 0.32* 134 2.
7 2 g q12h 0.47* 125 3.
17 2 g q8h 0.37 88.2* 3.
Ceftazidime 15 2 g q8h 0.81* 151 4.
12 2 g q8h 0.27* 3.
17 2 g q8h 0.51 63.7* 6.
18 2 g q8h 0.48 112* 5.
10 2 g q8h 0.23 112* 1.
49 2 g q8h or 6 g CI/day 0.67* 91.3
Meropenem 8 2 g q8h or 0.38* 156.7 2.
7 2 g LD+ 3 g CI/day 0.37* 128.3
16 1 g q8h 0.43 130.9* 2.
10 1 g q8h or 3 g CI/day 0.32* 226.7
10 1 g q8h 0.39* 191 2.
Piperacillin 8 12/1.5 g PIP/TAZ CI 0.33 286.7
8 4/0.5 PIP/TAZ q6h or q8h
27 4 g q6h 0.38 141.4* 2.
Ceftriaxone 54 2 g qd 0.28* 14.7 9.
10 2 g qd 0.28* 41.3 6.
Ertapenem 17 1 g CI/day 0.21* 43.2 4.
8 1 g qd 0.85* 200.5 5.
Flucloxacillin 10 0.29* 150.2 2.
Vd, volume of distribution; CL, clearance; Cmax, peak serum concentration; AUC, are
concentration; CI, continuous infusion; LD, loading dose; PIP, piperacillin; TAZ, tazobcompounded by both the limited number of patients
studied to date (Table 2) and the fact that different stud-
ies cite different PD targets. Finally, the contribution of
CRRT to total clearance is variable and dependent on
the degree of intrinsic renal function and potential other
organ dysfunction [82,83]. As a consequence, there are
no definitive dosing guidelines that can be used for all
critically ill patients who undergo CRRT. More import-
antly, some of the current dosing recommendations
have been shown to be inadequate, particularly against
resistant organisms [69,84], whereas toxicity from un-
necessarily high concentrations also has been reported
[63-65,82,85].
Is there a role for beta-lactam TDM in the critically ill?
Do beta-lactams meet the traditional criteria for requiring
TDM?
Drugs that are traditionally viewed as appropriate candi-
dates for TDM fulfill one or more of the criteria listed in












2 346 4 77% T>MIC [18]
37 68 310 32 34% T> 4xMIC [20]
5 249 [33]
42 305 7 80% T>MIC90 [19]
5 100% T>MIC90
37 66.56 324.02 [34]
75 277.31 [21]
48 124.4 331 4 92% T>MIC [35]
28 61.65 523.49 [34]
84 63 522 32 45% T> 4xMIC [20]
98 [36]
[22]
4 110.1 193.8 100% T>MIC [37]
117.5 100% T>MIC
05 35 132 8 57% T> 4xMIC [20]
[23]
13 46.6 99.5 0.25-1 100% T>MIC [38]
144 [24]
266.6
58 123 469 64 33% T> 4xMIC [20]
6 8 16% T>MIC [25]
4 204.9 [30]
15 90 418 2 25% T>MIC [39]
7 94.1 317.7 [26]
45 [27]
a under the concentration vs. time curve; MIC, minimum inhibitory
actam; *Data were converted considering 70 kg body weight.
Table 2 Pharmacokinetic parameters of selected beta-lactam antibiotics in critically ill patients undergoing CRRT






















Cefepime 4 2 g q8h CVVH or CVVHD PAN or PS 140-250 16.7-35 500-1000 100.5 l 4.6 0.6 111.5 27.2 0.76 [67]
5 1-4 g q12h or q24h CVVH PAN 150 16 44.6 - 94.9 12.9 0.46 834.7 -1,677.8 35.9 13 0.86 [66]
7 1-4 g q12h or q24h CVVHDF PAN 150 17 857-1020 25.7 -90.8 8.6 0.34 344.9 -1,306.8 46.8 26 0.78
8 2 g q12h CVVH or CVVHDF AN69 150 25.7* 1610* 43 6.17 0.55 379 72.8* [84]
Ceftazidime 12 2 g q8h CVVH PS 143 47 58.2 4.3 0.52* 344 98.7 32.1 0.69 [70]
7 3 g q24h CVVDHF AN69 150 25 1000 4 0.27* 2514 62 33.6 0.81 [69]
4 1-2 g q6h CVVH or CVVHDF AN69 or PS 130-140 25 500-1000 53.9-112 6.4 0.67 35.5-333.8 5-65.6 0.93 [82]
12 2 g q12h CVVH or CVVHDF AN69 150 25.7* 1610* 78 7.74 0.37 536 36.4* [84]
Meropenem 8 500 mg q12h CVVH AN69 10 26.7 39.5 3.63 105.3 82.94 24.42 0.91 [71]
5 1 g q12h CVVH AN69 150 16.7–33.3 5.16 0.39* 246 4.3 1.96 0.93 [86]
5 1 g q12h CVVDHF AN69 150 16.7 – 25 1000-1500
10 1 g q8h High volume CVVH AN69 250 66.7-100 56.6 4.3 0.2 166.5 100 58.3 0.93 [72]
15 0.5-1 g q8h or q12h CVVHDF AN 69 90-150 0.17-4.5 600-1500 5.1 0.47* 75 26.7 0.65 [87]
5 0.5 g q12h CVVH PAN 200 25-30 24.5 6.37 0.37 129.5 4.57 1.03 0.63 [88]
9 0.5 g q8h or q12h CVVH AN69 150-170 1.7-2.5 38.9 8.7 0.17* 52 22 1.17 [72]
9 1 g Stat CVVH PS 150 45.8 28.1 0.37* 118 143.7 49.7 0.24 [89]
Piperacillin/
tazobactam
6 4 g q12h/0.5 g q12h CVVH PS 100 13.3 7.7/13.9 64.8/40.3 [90]
CVVHDF 1000 6.7/11.6 84.3/52.2
2000 6.1/9.4 91.3/62.5
8 2 g/0.25 g or 4 g/0.5 g CVVHD AN69 150 1.3-3.3 1500 4.3/5.6 0.31/0.24 47/29.5 22/17 0.87/0.64 [91]
Ceftriaxone 6 2-4 g q24h CVVH PA 100-150 20-30 10.8 0.45* 16.6 0.69 [77]
Flucloxacillin 10 4 g q8h CVVH PA 169 57 139.1-179.7 4.9 0.69* 568 117.2 0.21 [79]
QB, blood flow rate; QUF, ultrafiltration rate; QDF, dialysate flow rate; RRT, renal replacement therapy; Sc, sieving coefficient; Sa, saturation coefficient; Vd, volume of distribution; CL, clearance; Cmax, peak serum
concentration; tH, half-life; AUC, area under the concentration vs time curve; CVVH, continuous venovenous hemofiltration; CVVHD, continuous venovenous hemodialysis; CVVHDF, continuous venovenous



















Table 3 Characteristics of drugs traditionally considered
to require TDM [92,93]
No. Criteria
1 Narrow therapeutic range/index
2 Drug toxicity may lead to hospitalization,
irreversible organ damage, and even death
3 No clearly defined clinical parameter that
allows dose adjustments
4 Correlation exists between serum concentration
and efficacy as well as toxicity
5 Unpredictable relationship between dose and
clinical outcome
6 Difficult to predict pharmacokinetics
(e.g. non-linear pharmacokinetics)
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fulfill the first of these criteria, a narrow therapeutic
index (e.g., aminoglycosides), TDM is commonly per-
formed. For drugs with a wider therapeutic index, in-
cluding beta-lactams, TDM has previously been
considered to be less clinically relevant because of a
lower risk of toxicity. However, TDM may be used, not
only to minimize toxicity but also to maximize efficacy
[92]. In fact, the primary goal of TDM may be to
optimize the clinical response to treatment, with a sec-
ondary goal being avoidance of adverse effects.
Further rationale for measuring therapeutic beta-
lactam concentrations relates to the absence of a “clearly
defined clinical parameter that allows dose adjustments”
(criterion 3). For conventional drugs that are subjected
to TDM, such as aminoglycosides, it is difficult to moni-
tor toxicity clinically unless drug levels are monitored,
because endpoints for toxicity are poorly defined [92].
Similarly, for beta-lactam antibiotic therapy, there is no
established or uniform clinical endpoint that reliably
describes resolution of infection and, therefore, adequate
dosing. Confirmation of dosing appropriateness using
antibiotic concentrations is therefore potentially useful.
The “relationship between dose and clinical outcome”
for beta-lactams also is unpredictable (criterion 5) due
to the variability in clinical response both between and
within patients from one dose to the next. A beta-lactam
dose that produces a therapeutic effect in one patient
may produce toxicity or no clinical response in another
patient most probably because of differences in drug dis-
tribution into different physiological compartments. Al-
though the PK of beta-lactams in the noncritically ill is
generally predictable, the rapidly changing acute patho-
physiology and organ dysfunction that occurs in the crit-
ically ill means that any assumptions about drug
concentrations are unreliable and dose-effect relation-
ships are unpredictable.
Finally, even though “non-linear PK” (criterion 6) is
not common for beta-lactams, drug accumulation andtoxicity can occur due to renal impairment. For example,
the accumulation of cefepime in critically ill patients
with acute renal failure has been reported to lead to
neurotoxicity [63-65,94]. Furthermore, attempts to pre-
vent such toxicity by using standard dose adjustment
algorithms [49] have been shown to be unsuccessful. For
piperacillin also, similar toxicities have been reported in
advanced renal failure at doses conventionally recom-
mended for patients with renal impairment [95,96].
Compressive reviews of neurotoxicity by beta-lactam
antibiotics have been published [85,94,97] and
emphasize the need for vigilant monitoring.
Studies assessing beta-lactam TDM in a clinical
environment
Although TDM of beta-lactam antibiotics in the critic-
ally ill patient population has previously been called for
[27,34,49,91,98], to date, only a few studies describing its
utility have been performed [16,45,99-102]. Roberts et al.
prospectively evaluated TDM in 236 ICU patients and
reported that beta-lactam dose adjustment was necessary
for 74.2% of patients; 50.4% of the total patients required
a dose increment after the first measurement. Their lim-
ited outcome findings indicate success rate of 87.3%
antibiotic course completion. More recently, the clinical
utility of beta-lactam TDM was prospectively examined
in a cohort of 50 burn injury patients in a ward environ-
ment. For 60% of patients, trough concentrations were
less than the target MIC and dose adjustment was
required. For patients achieving therapeutic targets, a
statistically significant shorter duration of antibiotic
therapy was described, thereby demonstrating the thera-
peutic utility of a TDM program [103].
A prospective study by Aubert et al. [45] assessed
serum ceftazidime concentrations in 92 ICU patients.
The authors reported that 37% of patients had inad-
equate ceftazidime concentrations and 27% had exces-
sive concentrations. Ceftazidime dosage was adjusted
accordingly to ensure therapeutic concentrations. Con-
nor et al. [104] reported a novel approach for measuring
piperacillin-tazobactam drug levels in patients receiv-
ing continuous veno-venous hemodialysis (CVVHD)
whereby CVVHD effluent was assayed to provide an
estimation of plasma drug concentrations for TDM. A
piperacillin TDM program in ICU patients using plasma
drug concentrations also has been evaluated by Blon-
diaux et al. [100]. The authors reported that 50% of
patients had plasma piperacillin concentrations within
the therapeutic target range after continuous infusion of
the initial dose and before TDM. Subsequent TDM-
guided dose adjustment increased this proportion to
75%.
For meropenem, Taccone et al.[102] recently demon-
strated that TDM-guided dose optimization resulted in a
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sively drug-resistant Pseudomonas aeruginosa. Interest-
ingly, the study demonstrates a rapid emergence of
extensively resistant strains most probably due to subin-
hibitory exposure arising from commonly used dose of
1 g q8h followed by 2 g q8h (MIC was 2 mg/L on day 1,
4 mg/L on day 6, and 8 mg/L a few days later). The
investigators performed TDM less frequently (initially
on days 2 and 5 of treatment) and were not able to ad-
just doses early enough to prevent the emergence of re-
sistance and/or therapeutic failure. Their observation,
however, presents a novel evidence to suggest frequent
TDM: perhaps daily and certainly in the earlier phase of
treatment. A case report by Pea et al. [101] also
described an intensive TDM process for meropenem and
daptomycin.
In summary, the available evidence supporting a bene-
ficial role for beta-lactam TDM in the critically ill is lim-
ited. The benefits of TDM may be most evident in
patients with severe sepsis as well as in infections with
organisms having high MIC. Whether or not TDM-
driven dose optimization results in improved clinical
outcomes, awaits evidence from a randomized, con-
trolled, clinical trial. It also should be noted that the spe-
cified PK/PD target has varied between studies
performed to date and to ensure the maximal benefit of
TDM an understanding of the appropriate PK/PD tar-
gets is essential.
Is there a defined PD target for beta-lactam TDM?
For beta-lactams, the best index that describes efficacy
is the time the free drug concentration remains above
MIC ( f T>MIC) [105]. However, the optimal f T>MIC is
controversial.
Animal studies suggest that maximal effects can be
achieved when f T>MIC is less than 100% of the dosing
interval, depending on the antibiotic and the organism
targeted [51,53,105]. In several studies of cephalosporins,
60–70% fT>MIC against Enterobacteriaceae and 40–50%
fT>MIC against Staphylococcus aureus have been
reported to produce maximal effect [105]. Earlier animal
studies also have indicated that Staphylococci have max-
imum killing at 50–60% fT>MIC, whereas 90–100%
fT>MIC are required for Gram-negative Bacilli and
Streptococci, presumably due to the absence of a postan-
tibiotic effect [51,53]. For carbapenems, which have rela-
tively high postantibiotic effect, bacteriostatic activity is
achieved at 20% fT>MIC and bactericidal effects are
observed at 40% fT>MIC [106].
Mouton et al. [107] reported in a dynamic in vitro
model that maintaining ceftazidime concentration
around or slightly above the MIC is not sufficient
enough to ensure prolonged efficacy and that targeting
f T>4xMIC provided sustained and better effect. Formeropenem, beneficial outcomes have been observed
when the target f T>4-5xMIC is maintained [73]. Finally,
Tam et al. [108] reported that exposure to 6xMIC is ne-
cessary for meropenem to suppress resistance emer-
gence against P. aeruginosa.
In patients, TDM using either 100% f T>MIC [103] or
100% f T>4-5xMIC [45,99,100,102,103] for several beta-
lactams has previously been reported. More recently,
54% fT>MIC for meropenem has been reported as signifi-
cant predictor of response in patients with pneumonia
[5]. This, and similar studies [7,102,109], suggest that a
higher duration of beta-lactam exposure may be
required for optimal clinical outcomes than that
reported in animal studies. Indeed, this higher exposure
may relate to impaired distribution of antibiotic into ISF
meaning that a higher plasma exposure is required to
achieve an ISF exposure that is equivalent to the animal
in vivo targets.
Given that many factors can affect the likelihood of a
positive outcome in the critically ill, beta-lactam treat-
ment should aim to attain the maximum exposure [79].
Targeting trough concentration (4-5xMIC) may decrease
the likelihood of suboptimal plasma concentrations. The
higher concentration would enable enhanced distribu-
tion of drug into tissues with deranged microcirculation
(e.g., septic shock) and improve impaired tissue beta-
lactam penetration [11,61,62]. In the absence of well-
conducted, prospective, clinical trials addressing the
therapeutic benefit of currently recommended PD tar-
gets, 100% f T>MIC could be considered a prudent PD
target for beta-lactams in the critically ill; albeit noncriti-
cally ill patients may only require minimal exposures of
40-70% f T>MIC.
Predicting MIC for TDM
The MIC of a target organism(s) is usually not available
upon initiation of therapy and may not become available
for 24–72 hours after specimens have been sent to a
microbiology laboratory. For this reason, epidemiological
data of MICs for pathogens can be useful, although there
may be considerable variability in the susceptibility of
organisms between different institutions within the same
geographic location. In cases when the causative organ-
ism has been isolated, MIC for the TDM target could be
determined by in vitro tests, such as the E-test [102]. If
these data are not available, an antibiogram for the local
institution should be used. Alternatively national guide-
lines, such as that produced by The French Microbiol-
ogy Society’s Antibiotics Committee [100], or other
databases, such as The European Committee on Anti-
microbial Susceptibility Testing (EUCAST), may be
highly useful [45,99,101,103].
In cases in which no organisms are isolated, the sus-
ceptibility break point of the least susceptible potential
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uginosa and K. pneumoniae are the most common
causes of pneumonias in an ICU, and piperacillin/
tazobactam is the preferred empiric therapy, the TDM that
targets the P. aeruginosa MIC (16 mg/L P. aeruginosa
vs. 8 mg/LK. pneumoniae) would be appropriate. Later,
dose adjustment could be based on the identified patho-
gen and associated MIC.
Beta-lactam assay for use in a TDM program
High performance liquid chromatography (HPLC) is the
most common assay technique used in studies of beta-
lactam TDM [16,45,99-102]. Verdier et al. [110] devel-
oped an HPLC assay method specifically targeting the
needs of routine TDM application, thus enabling simul-
taneous determination of 12 beta-lactams within 22 min-
utes. Another robust HPLC method described by
McWhinney et al. [111] analyzed 12 antibiotics simul-
taneously within a 7-minute run time. HPLC is, however,
a relatively slow technique that requires extensive sample
preparation and clean-up processes and, thus, is not suit-
able for urgent assay needs [112,113]. The relative cost
and requirement of specialized instrumentation also is
another drawback compared with other techniques, such
as immunochemical assays, which use cheaper, portable,
and easy-to-use instrumentations [114]. Immunochem-
ical assays have been used for other antibiotics for which
routine TDM is well established, such as aminoglyco-
sides and vancomycin [115,116]. However, the develop-
ment of such techniques for beta-lactams has been a
challenge [117,118]. To date, no technique allows simple
and rapid determination of unbound beta-lactam plasma
concentration, which is ideally required for TDM.
Conclusions
There is enormous PK variability of beta-lactam antibio-
tics in critically ill patients. The majority of evidence
suggests that empiric approaches to antibiotic dosing
may result in subtherapeutic antibiotic concentrations
and treatment failure or the emergence of antibiotic re-
sistance. The available studies also strongly support the
need for individualized dose optimization in the critically
ill, which supports the need for TDM. Despite the theor-
etical advantages, there remains no consistent use of
agreed PK/PD targets. Furthermore, none of the studies
have defined the impact of TDM on clinical outcome.
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